Patents by Inventor Jillian M. Hagel

Jillian M. Hagel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING
    Publication number: 20250025483
    Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.
    Type: Application
    Filed: September 19, 2024
    Publication date: January 23, 2025
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • C1-substituted isopropylamine fused heterocyclic mescaline derivatives
    Patent number: 12195439
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably C1-substituted isopropylamine fused heterocyclic mescaline derivatives, including C1-substituted isopropylamine fused dioxolane and fused dioxane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: January 14, 2025
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Kaveh Matinkhoo, David James Press, Glynnis Elizabeth Jensen, Jillian M. Hagel, Peter J. Facchini
  • Hydroxylated psilocybin derivatives and methods of using
    Patent number: 12187679
    Abstract: Disclosed are novel hydroxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced synthetically or biosynthetically.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: January 7, 2025
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Halogenated psilocybin derivatives and methods of using
    Patent number: 12138276
    Abstract: Disclosed are novel halogenated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced using a biosynthetic system which comprises cells comprising a psilocybin biosynthetic enzyme complement.
    Type: Grant
    Filed: May 6, 2024
    Date of Patent: November 12, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini
  • Multi-substituent psilocybin derivatives and methods of using
    Patent number: 12133856
    Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.
    Type: Grant
    Filed: December 20, 2023
    Date of Patent: November 5, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Multi-substituent psilocybin derivatives and methods of using
    Patent number: 12128058
    Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.
    Type: Grant
    Filed: December 20, 2023
    Date of Patent: October 29, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
    Publication number: 20240299427
    Abstract: Disclosed are novel halogenated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced using a biosynthetic system which comprises cells comprising a psilocybin biosynthetic enzyme complement.
    Type: Application
    Filed: May 6, 2024
    Publication date: September 12, 2024
    Inventors: Jillian M. Hagel, Peter J. Facchini
  • C4-carboxylic acid-substituted tryptamine derivatives and methods of using
    Patent number: 12077498
    Abstract: Disclosed are novel C4-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: July 5, 2023
    Date of Patent: September 3, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Ye Cai, Kaveh Matinkhoo, David James Press, Glynnis Elizabeth Jensen, Peter J. Facchini
  • C4-carboxylic acid-substituted tryptamine derivatives and methods of using
    Patent number: 12065404
    Abstract: Disclosed are novel C4-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: August 20, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Ye Cai, Kaveh Matinkhoo, David James Press, Glynnis Elizabeth Jensen, Peter J. Facchini
  • SUBSTITUTED ETHYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES
    Publication number: 20240246924
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably substituted ethylamine fused heterocyclic mescaline derivatives, including substituted ethylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 25, 2024
    Inventors: Kaveh Matinkhoo, David James Press, Jessica Lee, Charlie Cai, Jillian M. Hagel, Peter J. Facchini
  • SUBSTITUTED N-PROPYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES
    Publication number: 20240199568
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably substituted N-propylamine fused heterocyclic mescaline derivatives, including substituted N-propylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Application
    Filed: November 17, 2023
    Publication date: June 20, 2024
    Inventors: Kaveh Matinkhoo, David James Press, Glynnis Elizabeth Jensen, Charlie Cai, Jillian M. Hagel, Peter J. Facchini
  • Halogenated psilocybin derivatives and methods of using
    Patent number: 11998557
    Abstract: Disclosed are novel halogenated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced using a biosynthetic system which comprises cells comprising a psilocybin biosynthetic enzyme complement.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: June 4, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini
  • MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING
    Publication number: 20240173340
    Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.
    Type: Application
    Filed: December 20, 2023
    Publication date: May 30, 2024
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING
    Publication number: 20240122950
    Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.
    Type: Application
    Filed: December 20, 2023
    Publication date: April 18, 2024
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • FUSED HETEROCYCLIC MESCALINE DERIVATIVES
    Publication number: 20240116907
    Abstract: Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Application
    Filed: August 4, 2023
    Publication date: April 11, 2024
    Inventors: Peter J. Facchini, Jillian M. Hagel, Chang-Chun Ling, Charlie Cai, David James Press, Glynnis Elizabeth Jensen, Jessica Bik-Jing Lee, Kaveh Matinkhoo
  • AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
    Publication number: 20240116866
    Abstract: Disclosed are novel aminated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The aminated psilocybin derivative compounds may be chemically synthesized.
    Type: Application
    Filed: November 16, 2023
    Publication date: April 11, 2024
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • C-carbonothioate-substituted tryptamine derivatives and methods of using
    Patent number: 11945778
    Abstract: Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: April 2, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Kaveh Matinkhoo, Peter J. Facchini
  • Nitrilated psilocybin derivatives and methods of using
    Patent number: 11931338
    Abstract: Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: March 19, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Multi-substituent psilocybin derivatives and methods of using
    Patent number: 11918594
    Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.
    Type: Grant
    Filed: September 29, 2022
    Date of Patent: March 5, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Prenylated psilocybin derivatives and methods of using
    Patent number: 11891359
    Abstract: Disclosed are novel prenylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced in vitro or in vivo using a biosynthetic system which comprises cells comprising a prenyl transferase, and, optionally, additional enzymes, including a decarboxylase, and an N-acetyl transferase.
    Type: Grant
    Filed: September 29, 2022
    Date of Patent: February 6, 2024
    Assignee: ENVERIC BIOSCIENCES CANADA INC.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Xue Chen